ANIX:NSD-Anixa Biosciences, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 2.49

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

0.17M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

N/A

USD43.89B 61.31 36.64
DXCM DexCom, Inc

N/A

USD38.52B 173.65 108.43
IDXX IDEXX Laboratories, Inc

N/A

USD32.14B 69.09 46.81
EXAS Exact Sciences Corporation

N/A

USD14.67B N/A N/A
GH Guardant Health, Inc

N/A

USD11.12B N/A N/A
ICLR ICON Public Limited Company

N/A

USD9.64B 29.89 20.21
QDEL Quidel Corporation

N/A

USD8.76B 55.12 34.17
PRAH PRA Health Sciences, Inc

N/A

USD6.22B 29.56 17.69
NTRA Natera, Inc

N/A

USD5.77B N/A N/A
SYNH Syneos Health, Inc

N/A

USD5.36B 28.65 16.75

ETFs Containing ANIX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.09% 31% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.09% 31% F 33% F
Trailing 12 Months  
Capital Gain -36.80% 24% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.80% 24% F 20% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.98% N/A N/A 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.98% N/A N/A 12% F
Risk Return Profile  
Volatility (Standard Deviation) 21.91% N/A N/A 65% D
Risk Adjusted Return -77.50% N/A N/A 7% F
Market Capitalization 0.06B 25% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.57 32% F 19% F
Price / Cash Flow Ratio -12.49 76% C 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -147.19% 14% F 8% F
Return on Invested Capital -222.86% 8% F 3% F
Return on Assets -74.88% 7% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.34 37% F 38% F
Short Percent 6.58% 43% F 31% F
Beta 1.28 43% F 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector